Immuno-oncology – Optimum Strategic Communications

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

14 March 2024/in Client news

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

1 February 2024/in Client news

Italian investors, NEVA SGR, LIFTT and Simon Fiduciaria, join the existing syndicate Additional investment brings the total Series B financing to £31.1 million (approx. USD $39.5 million) London, UK, 1 February 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B […]

Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO Immuno-Oncology Congress 2023

8 December 2023/in Client news

Updated safety and clinical efficacy data presented at leading immuno-oncology conference Exploratory studies suggest roginolisib boosts antitumoral immunity, whilst simultaneously disrupting tumor survival mechanisms Data suggest the potential of radiomics to assess changes in lesions over time, adding value above RECIST (Response Evaluation Criteria in Solid Tumors) Geneva, Switzerland and Amsterdam, The Netherlands, 8 December […]

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

5 December 2023/in Client news

Experienced, innovative biotech and pharma leader with demonstrated success in discovery and development of new therapeutic technologies Amsterdam, NLD – 5 December 2023 – Kling Bio (“Kling” or “the Company”), a biotech company developing antibody-based drugs against targets identified from its immortalized B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as […]